- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05074836
Milk Supplementation and Bone Health in Children
Effects of Yili Child Formula Milk on Bone Health in 4-6 Year Children: a 12-month Randomized Controlled Trial
Objectives: to examine the effects of a Yili child formula milk and regular milk on bone health and growth in young children.
Study design: cluster randomized controlled trial.
Setting: kindergartens in Hui-ning County of Gansu Province, China (north west).
Participants: >=246 apparent healthy children aged 4-6 years old.
Interventions:
(I) Yili child formula milk (QQ star formula, SCI-PRO NUTR5+6TM), 195 ml *2 /day; (II) Yili regular milk (pure milk), 195ml*2 /day; (III) Controls: about 50g/d grain foods (containing 20-30 g carbohydrates), e.g. bread.
Interventional Duration: 12 months.
Outcome measures: determined at 0, 6 and 12 months post treatments. Primary outcomes: bone density and bone mineral contents at the forearm and heel, bone biomarkers.
Secondary outcomes: (1) anthropometric indices: weight, height, waist circumference, etc.; (2) immune status.
Other measures: dietary intakes, physical activities, general information, medical information, adverse of side effects.
Data Analyses: The one-year changes and percent changes in the primary and secondary outcomes will be compared among the 3 groups.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Anticipado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Gangshu
-
Lanzhou, Gangshu, Porcelana, 730000
- LanZhou University
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Aged between 4-6 years;
- female and male
- Can be enrolled into kindergarten/school as a normal child.
- Be willing to drinking milk daily.
Exclusion Criteria:
- Milk allergy or intolerance, did not to be used to drinking milk;
- Had the following diseases/conditions confirmed by a hospital: serious diseases of heart, liver, kidney, brain, hematopoietic system, immunity, thyroid or cancer that need to be hospitalization for more than 1 week or take medication(s) for more than 1 month with the past two years.
- having infectious diseases, e.g., tuberculosis, hepatitis, etc.
- Taking vitamin D, calcium tables or nutrient package;
- Consumed more than 3 times (>600ml) milk each week in the previous month.
- Be not willing to provide informed consent, or have other conditions that were considered to be unsuitable for the study by the investigators.
- Increases of body health were out of the range between 5-8 cm in the last year.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Formula Milk
Formula milk designed for young children aged over 3 years; Dosage: 195 ml/time; Frequence: 2 times /day; Duration: 12 months |
Brand name: Yili (QQ star formula milk); Type: SCI-PRO NUTRI 5+6TM formula milk designed for young children aged over 3 years; Dosage: 195ml*2/d; Intervention duration: 12 months |
Comparador activo: Regular milk
Regular milk (pure milk); Dosage: 195 ml/time; Frequence: 2 times /day; Duration: 12 months |
Brand name: Yili; Type: regular milk (pure milk); Dosage: 195ml*2/d; Intervention duration: 12 months |
Otro: Control foods
Grain foods: e.g., bread; Dosage: 20-40 g/time; Frequence: 2 times /day; Duration: 12 months |
Brand: N/A; Food type: grain foods (e.g., bread); Dosage: 20-40g * 2/d grain foods Intervention duration: 12 months |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Change from baseline bone mineral density (BMD) at 12 months
Periodo de tiempo: 0 and 12 months
|
BMD (g/cm2) determined by a dual energy x-ray absorptiometry (DXA) at the left forearm and heel
|
0 and 12 months
|
Change from baseline bone mineral density (BMD) at 6 months
Periodo de tiempo: 0 and 6 months
|
BMD (g/cm2) determined by DXA at the left forearm and heel
|
0 and 6 months
|
Change from baseline bone mineral contents (BMC) at 12 months
Periodo de tiempo: 0 and 12 months
|
BMC (g) determined by DXA at the left forearm and heel.
|
0 and 12 months
|
Change from baseline bone mineral contents (BMC) at 6 months
Periodo de tiempo: 0 and 6 months
|
BMC (g) determined by DXA at the left forearm and heel.
|
0 and 6 months
|
Change from baseline of bone-specific alkaline phosphatase at 12 months
Periodo de tiempo: 0 and 12 months
|
Bone turnover marker 1: Bone-specific alkaline phosphatase
|
0 and 12 months
|
Change from baseline of bone-specific alkaline phosphatase at 6 months
Periodo de tiempo: 0 and 6 months
|
Bone turnover marker 1: Bone-specific alkaline phosphatase
|
0 and 6 months
|
Change from baseline of osteocalcin at 12 months
Periodo de tiempo: 0 and 12 months
|
Bone turnover marker 2: osteocalcin
|
0 and 12 months
|
Change from baseline of osteocalcin at 6 months
Periodo de tiempo: 0 and 6 months
|
Bone turnover marker 2: osteocalcin
|
0 and 6 months
|
Change from baseline of C-terminal telopeptide of type I collagen at 12 months
Periodo de tiempo: 0 and 12 months
|
Bone turnover marker 3: C-terminal telopeptide of type I collagen
|
0 and 12 months
|
Change from baseline of C-terminal telopeptide of type I collagen at 6 months
Periodo de tiempo: 0 and 6 months
|
Bone turnover marker 3: C-terminal telopeptide of type I collagen
|
0 and 6 months
|
Change from baseline of tartrate resistant acid phosphatase at 12 months
Periodo de tiempo: 0 and 12 months
|
Bone turnover marker 4: tartrate resistant acid phosphatase
|
0 and 12 months
|
Change from baseline of tartrate resistant acid phosphatase at 6 months
Periodo de tiempo: 0 and 6 months
|
Bone turnover marker 4: tartrate resistant acid phosphatase
|
0 and 6 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Change from baseline body weight at 12 months
Periodo de tiempo: 0 and 12 months
|
Anthropometric indices: body weight
|
0 and 12 months
|
Change from baseline body height at 12 months
Periodo de tiempo: 0 and 12 months
|
Anthropometric indices: body height
|
0 and 12 months
|
Change from baseline biomarker of body growth at 12 months
Periodo de tiempo: 0 and 12 months
|
Biomarker of body growth: insulin-like growth factor 1
|
0 and 12 months
|
Change from baseline immune globulin M (Ig M)at 12 months
Periodo de tiempo: 0 and 12 months
|
Immune status: Blood Ig M
|
0 and 12 months
|
Change from baseline immune globulin G (Ig G)at 12 months
Periodo de tiempo: 0 and 12 months
|
Immune status: Blood Ig G
|
0 and 12 months
|
Change from baseline immune globulin G (Ig A)at 12 months
Periodo de tiempo: 0 and 12 months
|
Immune status: Blood Ig A
|
0 and 12 months
|
Change from baseline whit blood cell at 12 months
Periodo de tiempo: 0 and 12 months
|
Immune status: whit blood cell
|
0 and 12 months
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Concentrations of blood total 25-hydroxide-vitamin D (25-OH-VD)
Periodo de tiempo: 0, 6 and 12 months
|
Serum 25-OH-VD
|
0, 6 and 12 months
|
Concentrations of blood parathyroid Hormone (PTH)
Periodo de tiempo: 0, 6 and 12 months
|
Serum PTH
|
0, 6 and 12 months
|
Nutritional status 1: Body weight
Periodo de tiempo: 0, 4, 8 and 12 months
|
Body weight (in kg)
|
0, 4, 8 and 12 months
|
Nutritional status 2: waist circumference
Periodo de tiempo: 0, 4, 8 and 12 months
|
Waist circumference (in cm)
|
0, 4, 8 and 12 months
|
Nutritional status 3: middle-arm circumference
Periodo de tiempo: 0, 4, 8 and 12 months
|
Middle-arm circumference (in cm)
|
0, 4, 8 and 12 months
|
Nutritional status 4: skinfold thickness
Periodo de tiempo: 0, 4, 8 and 12 months
|
Skinfold thickness (in mm)
|
0, 4, 8 and 12 months
|
Total consumption of milk and dairy food
Periodo de tiempo: 0, 4, 8 and 12 months
|
Total consumption of milk and dairy food (in ml/d)
|
0, 4, 8 and 12 months
|
Consumption of dietary energy
Periodo de tiempo: 0, 4, 8 and 12 months
|
Consumption of dietary energy (in kcal/d)
|
0, 4, 8 and 12 months
|
Consumption of dietary protein
Periodo de tiempo: 0, 4, 8 and 12 months
|
Consumption of dietary protein (in g/d)
|
0, 4, 8 and 12 months
|
Consumption of dietary calcium
Periodo de tiempo: 0, 4, 8 and 12 months
|
Consumption of dietary calcium (in mg/d)
|
0, 4, 8 and 12 months
|
Number of participants with treatment-related adverse events
Periodo de tiempo: 0, 4, 8 and 12 months
|
Adverse events : assessed by using questionnaires of medical conditions, medications related to milk intake
|
0, 4, 8 and 12 months
|
Child behaviors
Periodo de tiempo: 0 and 12 months
|
Child behaviours: assessed by using a Child behavior Questionnaire-- parent version.
The minimum and maximum values: 26-78; higher scores mean worse outcome.
|
0 and 12 months
|
Physical activity
Periodo de tiempo: 0, 4, 8 and 12 months
|
Physical activity (in MET, h/week): assessed by a Child Physical Activity Questionnaire
|
0, 4, 8 and 12 months
|
Concentrations of serum calcium
Periodo de tiempo: 0, 6 and 12 months
|
Serum calcium (mmol/L)
|
0, 6 and 12 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Yuming Chen, Ph.D., Sun Yat-sen University
- Silla de estudio: Zhifu Zhao, M. Phil, Inner Mongolia Dairy Technology Research Institute Co., Ltd.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- SYSU-51000-20210723-0001
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Formula milk
-
University of PittsburghNational Institute of Nursing Research (NINR)Terminado
-
Loyola UniversityReclutamientoEstrés | Desarrollo InfantilEstados Unidos
-
KK Women's and Children's HospitalAún no reclutandoFalta de crecimiento | Lactante de muy bajo peso al nacer | Leche Materna de DonanteSingapur
-
Columbia UniversityReclutamientoFalta de crecimiento | Retraso del crecimiento | Precocidad; Extremo | Trastornos de la nutrición infantil | Falta de crecimiento en el recién nacidoEstados Unidos
-
The Hospital for Sick ChildrenWorld Health OrganizationTerminado